Bioinformatics analysis identifies precision treatment with paclitaxel for hepatocellular carcinoma patients harboring mutant tp53 or wild-type ctnnb1 gene

Jiunn Chang Lin, Tsang Pai Liu, Vivin Andriani, Muhammad Athoillah, Chih Yang Wang, Pei Ming Yang

Research output: Contribution to journalArticlepeer-review

Abstract

Hepatocellular carcinoma (HCC) is an aggressive and chemoresistant cancer type. The development of novel therapeutic strategies is still urgently needed. Personalized or precision medicine is a new trend in cancer therapy, which treats cancer patients with specific genetic alterations. In this study, a gene signature was identified from the transcriptome of HCC patients, which was correlated with the patients’ poorer prognoses. This gene signature is functionally related to mitotic cell cycle regulation, and its higher or lower expression is linked to the mutation in tumor protein p53 (TP53) or catenin beta 1 (CTNNB1), respectively. Gene–drug association analysis indicated that the taxanes, such as the clinically approved anticancer drug paclitaxel, are potential drugs targeting this mitotic gene signature. Accordingly, HCC cell lines harboring mutant TP53 or wild-type CTNNB1 genes are more sensitive to paclitaxel treatment. Therefore, our results imply that HCC patients with mutant TP53 or wild-type CTNNB1 genes may benefit from the paclitaxel therapy.

Original languageEnglish
Article number1199
JournalJournal of Personalized Medicine
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 2021

Keywords

  • Bioinformatics
  • Hepatocellular carcinoma
  • Precision medicine
  • Taxanes

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint

Dive into the research topics of 'Bioinformatics analysis identifies precision treatment with paclitaxel for hepatocellular carcinoma patients harboring mutant tp53 or wild-type ctnnb1 gene'. Together they form a unique fingerprint.

Cite this